Related Experiment Video
Updated: Jul 10, 2026
14:25
Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans
Published on: September 21, 2019
Endocannabinoids and neurodegenerative diseases
Vincenzo Micale1, Carmen Mazzola, Filippo Drago
1Department of Experimental and Clinical Pharmacology, University of Catania, Medical School, Catania, Italy.
Pharmacological Research
|October 24, 2007
Summary
The endocannabinoid system, involving receptors and ligands, plays a role in neurodegenerative diseases like Alzheimer's and Huntington's. Modulating this system offers potential therapeutic strategies for these conditions.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- The endocannabinoid system (ECS) comprises cannabinoid receptors (CB1, CB2), endogenous ligands (anandamide), and enzymes (FAAH, MGL).
- The ECS is involved in cognitive, motor, and immune functions, making it relevant to neurodegenerative diseases.
Purpose of the Study:
- To review the role of the ECS in Alzheimer's disease (AD) and Huntington's disease (HD) pathophysiology.
- To discuss the therapeutic potential of ECS modulation for neurodegenerative diseases.
Main Methods:
- Review of existing literature on the ECS in AD and HD models and human studies.
- Analysis of data on imbalances in ECS components in AD and HD.
- Examination of preclinical and clinical studies on compounds targeting the ECS.
Main Results:
- AD shows an imbalance in the ECS, with altered CB1/CB2 receptor expression and increased FAAH, suggesting roles in inflammation and neuroprotection.
- HD is characterized by reduced ECS signaling, including loss of CB1 receptors and decreased endocannabinoids in motor control areas.
- Compounds modulating the ECS (agonists, antagonists, enzyme inhibitors) are being investigated for their effects on disease symptoms and progression.
Conclusions:
- The ECS is significantly implicated in the pathophysiology of AD and HD.
- Targeting the ECS presents a promising therapeutic avenue for managing neurodegenerative diseases.
Related Concept Videos
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:22Gut-Brain Axis
The gut–brain axis is a bidirectional communication system that connects the gastrointestinal tract and the brain. This interaction is mediated through multiple pathways, including the vagus nerve, hormonal signals, immune responses, and chemical messengers produced by gut microbes.Microbial Contributions to Brain FunctionGut microbiota contributes significantly to brain function by producing neuroactive compounds. These include neuroactive compounds that influence neurotransmitters such as...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...